{"id":952139,"date":"2026-04-16T11:54:16","date_gmt":"2026-04-16T15:54:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/"},"modified":"2026-04-16T11:54:16","modified_gmt":"2026-04-16T15:54:16","slug":"adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/","title":{"rendered":"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation – Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky"},"content":{"rendered":"

\nADMA Biologics reported $510 million in 2025 revenue, a year-over-year increase of 20%. A short-seller report alleges actual revenues declined 3% year-over-year
\n<\/h2>\n
\n

NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) — ADMA Biologics (NASDAQ: ADMA) told investors on February 25, 2026, that 2025 revenue was $510 million — representing 20% year-over-year growth. A short-seller report published by Culper Research alleges the real figure reflects a 3% year-over-year decline. ADMA shareholders who lost money are encouraged to submit their information now<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n

On the Q4 2025 earnings call, CEO Adam Grossman stated \u201cASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.\u201d Culper Research\u2019s short report contends ASCENIV only achieved its growth on the back of \u201cclassic channel stuffing.\u201d ADMA\u2019s annual report further claimed its commercial execution was \u201cexpected to accelerate demand utilization while maintaining cost discipline.\u201d Yet, Culper contends that members of ADMA\u2019s distributor attested that \u201cunderlying demand \u2018is not really growing.\u2019\u201d<\/p>\n

The gap between the reported 20% revenue growth and the alleged 3% decline represents a substantial divergence. ADMA stock dropped sharply immediately following publication of the short-seller report on March 24, 2026 and throughout the following days.<\/p>\n

Shareholders who purchased ADMA stock and suffered losses may click here to discuss their legal rights<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n

Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.<\/p>\n

Frequently Asked Questions About the ADMA Investigation<\/p>\n

\n Q: Who is eligible to participate in the ADMA investor Investigation?<\/strong> A: Investors who purchased ADMA stock and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.<\/p>\n

\n Q: How much did ADMA stock drop?<\/strong> A: Shares fell by approximately $2.26 (16.63%) on March 24, 2025, and another $1.70 (15%) the following day.<\/p>\n

\n Q: What specific misstatements does the ADMA investigation allege?<\/strong> A: The investigation examines whether ADMA made materially false or misleading statements regarding revenue growth, product-level gross margins, and balance sheet condition during 2025. A short-seller report alleges actual revenues declined 3% versus the 20% annual growth reported.<\/p>\n

\n Q: What do ADMA investors need to do right now?<\/strong> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com<\/a> or (212) 363-7500. No immediate action is required to remain eligible as a class member.<\/p>\n

\n Q: What happens after I contact Levi & Korsinsky?<\/strong> A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.<\/p>\n

\n Q: What does it cost me to participate?<\/strong> A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.<\/p>\n

CONTACT:<\/p>\n

Levi & Korsinsky, LLP<\/p>\n

Joseph E. Levi, Esq.<\/p>\n

Ed Korsinsky, Esq.<\/p>\n

33 Whitehall Street, 27th Floor<\/p>\n

New York, NY 10004<\/p>\n

\n jlevi@levikorsinsky.com<\/a>\n <\/p>\n

Tel: (212) 363-7500<\/p>\n

Fax: (212) 363-7171<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ADMA Biologics reported $510 million in 2025 revenue, a year-over-year increase of 20%. A short-seller report alleges actual revenues declined 3% year-over-year NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) — ADMA Biologics (NASDAQ: ADMA) told investors on February 25, 2026, that 2025 revenue was $510 million — representing 20% year-over-year growth. A short-seller report published by Culper Research alleges the real figure reflects a 3% year-over-year decline. ADMA shareholders who lost money are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. On the Q4 2025 earnings call, CEO Adam Grossman stated \u201cASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.\u201d Culper Research\u2019s … <\/p>\n

Continue reading “ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation – Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952139","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ADMA Biologics reported $510 million in 2025 revenue, a year-over-year increase of 20%. A short-seller report alleges actual revenues declined 3% year-over-year NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) — ADMA Biologics (NASDAQ: ADMA) told investors on February 25, 2026, that 2025 revenue was $510 million — representing 20% year-over-year growth. A short-seller report published by Culper Research alleges the real figure reflects a 3% year-over-year decline. ADMA shareholders who lost money are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. On the Q4 2025 earnings call, CEO Adam Grossman stated \u201cASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.\u201d Culper Research\u2019s … Continue reading "ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation – Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T15:54:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation – Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky\",\"datePublished\":\"2026-04-16T15:54:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/\"},\"wordCount\":518,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/\",\"name\":\"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=\",\"datePublished\":\"2026-04-16T15:54:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation – Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/","og_locale":"en_US","og_type":"article","og_title":"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky - Market Newsdesk","og_description":"ADMA Biologics reported $510 million in 2025 revenue, a year-over-year increase of 20%. A short-seller report alleges actual revenues declined 3% year-over-year NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) — ADMA Biologics (NASDAQ: ADMA) told investors on February 25, 2026, that 2025 revenue was $510 million — representing 20% year-over-year growth. A short-seller report published by Culper Research alleges the real figure reflects a 3% year-over-year decline. ADMA shareholders who lost money are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. On the Q4 2025 earnings call, CEO Adam Grossman stated \u201cASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.\u201d Culper Research\u2019s … Continue reading \"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation – Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-16T15:54:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation – Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky","datePublished":"2026-04-16T15:54:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/"},"wordCount":518,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/","name":"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=","datePublished":"2026-04-16T15:54:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDg1OSM3NTM4MzYyIzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-may-seek-to-lead-the-potential-class-action-after-claims-company-overstated-financial-metrics-levi-kor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation – Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952139"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}